Prosecution Insights
Last updated: November 08, 2026
Application No. 18/529,406

PET TRACER

Non-Final OA §103
Filed
Dec 05, 2023
Priority
Dec 14, 2022 — SE 2251463-2
Examiner
KATAKAM, SUDHAKAR
Art Unit
1658
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Antaros Tracer AB
OA Round
1 (Non-Final)
75%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
98%
With Interview

Examiner Intelligence

Grants 75% — above average
75%
Career Allowance Rate
977 granted / 1307 resolved
+14.8% vs TC avg
Strong +23% interview lift
Without
With
+23.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 6m
Avg Prosecution
83 currently pending
Career history
1385
Total Applications
across all art units

Statute-Specific Performance

§101
1.7%
-38.3% vs TC avg
§103
44.6%
+4.6% vs TC avg
§102
13.0%
-27.0% vs TC avg
§112
25.4%
-14.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1307 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority Acknowledgments are made that this application claims the priority to the following: PNG media_image1.png 69 228 media_image1.png Greyscale . Information Disclosure Statement The information disclosure statement (IDS), dated 06/22/2024, not comply with the provisions of 37 CFR 1.97, 1.98 and MPEP § 609, since the provided document is blurry and not readable. Applicants are requested to provide good quality of document, preferably the whole document. Response to Restriction Applicant's response to restriction requirement and election of group I corresponding to claims 1-11 in the reply filed on 08/24/2026 is acknowledged. The examiner also acknowledges applicants election of Al18F-RESCA-Z09591 (claim 8), as the conjugate binding molecule species, including PDFG beta polypeptide (the Z-molecule comprising the amino acid sequence SEQ ID NO:237), the radionuclide (Al18F), and the linker (RESCA). and providing a single species for the claimed compound. Claim 12 is withdrawn from consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species, there being no allowable generic or linking claim. The claims 1-11 are examined, in light of elected species, on merits in this office action. Claim Objections/Sequence Compliance Claim 10 is objected to because of the following informalities: 37 CFR 1.821(d) states that where the claims recite a sequence the sequence identifier must be included. The applicants have provided a sequence listing, but have not included the corresponding sequence identifiers in the claim. Examiner also request applicants to search for sequences missing SEQ ID NOs in the specification. In claim 3, line 2, the “PBM” should be in parenthesis. Appropriate correction is required. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-11 are rejected under 35 U.S.C. 103 as being unpatentable over Cleeren (Theranostics, 2017, vol.7, issue 11, 2924-2939) in view of Tolmachev (The Journal of Nuclear Medicine, Feb 2014, vol.55, No.2, 294-300) and Lindborg (EP2231860B1). For claims 1-2: Cleeren teaches the following conjugate: PNG media_image2.png 141 139 media_image2.png Greyscale , wherein C Al18F is RESCA [see Fig.1]. Cleeren exemplified the above conjugate with proteins, viz., HSA [see Fig.2], AbV4m119 [see Fig.4] and PEP04314 [see Fig.6]. Cleeren further teaches that current methods for radiolabeling biomolecules with fluorine-18 are laborious and require multistep procedures with moderate labeling yields. The Al18F-labeling strategy involves chelation in aqueous medium of aluminum mono[18F]fluoride ({Al18F}2+) by a suitable chelator conjugated to a biomolecule. Therefore, we designed a new restrained complexing agent (RESCA) for application of the AlF strategy at room temperature. This generic radiolabeling method has the potential to be a kit-based fluorine-18 labeling strategy, and could have a large impact on PET radiochemical space, potentially enabling the development of many new fluorine-18 labeled protein-based radiotracers. [See Abstract and Introduciton]. Difference is that Cleeren is silent on applicants elected PDGF-Rβb binding polypeptide. This difference can be cured by the following teachings: Tolmachev teaches PDGF Rβb binding polypeptide, viz., Z09591 in the conjugate 111In-DOTA-Z09591 [see abstract], wherein Z09591 is identical to applicants elected species. Lindborg teaches applicants PDGF-Rβb binding polypeptide sequences and PBM sequences [see 0005-0030]. In light of advantages of Al18F RESCA, as taught or evidenced from the teachings of Cleeren, one would be motivated to replace polypeptide in the conjugate of Cleeren with desired polypeptide or applicants elected polypeptide from the teachings of Tolmachev and Lindborg. There is also a reasonable expectation of success to arrive at applicants claimed conjugate, because structurally similar conjugate is known from the teachings of Tolmachev. For claims 3-5: Lindborg teaches the following sequence: PNG media_image3.png 375 834 media_image3.png Greyscale , which is identical or at least overlaps with applicants sequences. [See 0005-0030]. Lindborg further teaches the following sequence: PNG media_image4.png 43 831 media_image4.png Greyscale . The above sequence is identical to applicants claimed first sequence in claim 5. For claims 6-8: Applicants elected sequence Z09591 is known, see in the teachings of Tolmachev, see above For claims 1-2. For claims 9: Cleeren teaches a linker, which is in between RESCA and polypeptide [see Fig.6]. For claim 10: Cleeren teaches their conjugate for positron emission tomography imaging [see title and abstract]. For claim 11: The recited limitation is intended use and does not have any weight. Alternatively, Cleeren teaches a conjugate for PET imaging and the property or utility depends on the polypeptide in the conjugate. For example, if the polypeptide is PDGF-Rβb binding polypeptide sequences [see teachings of Tolmachev and Lindborg], then it can be used in the assessment of fibrosis. Based on the above established facts from the cited prior art, it appears that all the claimed elements, i.e, applicants individual components in the conjugate, were known in the prior art, and one skilled person in the art could have combined the elements as claimed by known relationships, with no change in their respective functions, and the combination would have yielded predictable results to one of ordinary skill in the art. The motivation to combine the art can arise from the expectation that the prior art elements will perform their expected functions to achieve their expected results when combined for their common known purpose. See MPEP 2144.07. Therefore, it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention by taking the advantage of the teaching of the above cited reference and to make the instantly claimed conjugate with a reasonable expectation of success. A combination of prior art references is only proper if a person of ordinary skill in the art (POSA) at the time of the invention, faced with the same problem, would have been motivated to combine their teachings with a reasonable expectation of success. See KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007). Here, the technical fields and problems addressed by the references are not distinct from that of the present claimed invention. The strongest rationale for combining references is a recognition, expressly or impliedly in the prior art or drawn from a convincing line of reasoning based on established scientific principles or legal precedent, that some advantage or expected beneficial result would have been produced by their combination. In re Sernaker, 702 F.2d 989, 994-95, 217 USPQ 1, 5-6 (Fed. Cir. 1983). In the instant case, one is simply substituting a linker from Bonny into the composition of Abrahmsen. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUDHAKAR KATAKAM whose telephone number is (571)272-9929. The examiner can normally be reached 8:30 am to 5 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Melissa Fisher can be reached at 571-270-7430. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SUDHAKAR KATAKAM/Primary Examiner, Art Unit 1658
Read full office action

Prosecution Timeline

Dec 05, 2023
Application Filed
Oct 27, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780875
POLYPEPTIDES INCLUDING A BETA-TRICALCIUM PHOSPHATE-BINDING SEQUENCE AND USES THEREOF
3y 2m to grant Granted Nov 03, 2026
Patent 12780876
CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF
1y 1m to grant Granted Nov 03, 2026
Patent 12766196
PHARMACEUTICAL COMPOSITION COMPRISING GLUCAGON/GLP-1/GIP TRIPLE AGONIST OR LONG-ACTING CONJUGATE THEREOF FOR PREVENTING OR TREATING VASCULITIS
3y 6m to grant Granted Oct 20, 2026
Patent 12760066
BIVALENT ANTAGONISTS OF INHIBITORS OF APOPTOSIS PROTEINS
5y 0m to grant Granted Oct 13, 2026
Patent 12760070
CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF
1y 0m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
75%
Grant Probability
98%
With Interview (+23.3%)
2y 6m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1307 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month